A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin
+ Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to
prevent cutaneo-mucinous toxicities.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Non-progression rate after 6 cycles
6 months
No
Laure CHAUVENET, MD, PHD
Principal Investigator
Hôpital HOTEL DIEU - Paris
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
CAPYTTOLE
NCT00524810
February 2004
June 2009
Name | Location |
---|